AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6142717
Drug: Liquid oral
RxNorm normalized name: M-End Liquid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution of bromazepam (3 mg)
Trial: 6142717
Drug: Liquid oral
RxNorm normalized name: M-End Liquid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution of bromazepam (1.5 mg)
Trial: 31540613
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for cocaine use disorders (CUD)
Trial: 27184297
Drug: Attention Bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Bias Modification Therapy (ABMT)
Trial: 23103033
Drug: Control stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control stents (bare metal or drug-eluting)
Trial: 20840318
Drug: Zibotentan 15
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 15 mg
Trial: 20840318
Drug: Zibotentan 10
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 10 mg
Trial: 17880872
Drug: Intralesional autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional autologous blood injection
Trial: 16115973
Drug: Fentanyl injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl injection over 2 seconds
Trial: 16115973
Drug: Fentanyl injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl injection over 15 seconds
Trial: 16115973
Drug: Fentanyl injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl injection over 30 seconds
Trial: 7957497
Drug: rhEPO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (500 U kg‐1 body weight twice weekly during a 3 week period)
Trial: 3669729
Drug: MgSO4 inhalation
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 inhalation
Trial: 31960624
Drug: Tezepelumab 35
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 35 mg
Trial: 31960624
Drug: Tezepelumab 105
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 105 mg
Trial: 31960624
Drug: Tezepelumab 280
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 280 mg
Trial: 20864916
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 (oxaliplatin 85 mg/m², leucovorin 350 mg, and 5-fluorouracil 400 mg/m² bolus; 2.4 g/m² infusion, 46 h) day 1; bevacizumab 5 mg/kg on day 1; cetuximab 400 mg/m² on day 1, then 250 mg/m² on days 1 and 8, every 14 days until progressive disease (PD)
Trial: 8977914
Drug: Calcium carbasalate
RxNorm normalized name: carbasalate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbasalate (equivalent to aspirin 325 mg daily, single dose 6 hours post-operation, repeated for 7 days)
Trial: 1587379
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms 17 beta-estradiol (Vagifem) administered as a vaginal tablet, treated once daily for 2 weeks and twice a week for 10 weeks
Trial: 31645444
Drug: Adenovirus Type
RxNorm normalized name: Adenovirus types 4 and 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus Type 5-Based HIV-1 Vaccines
Trial: 24059649
Drug: Inulin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (10 g/d for 8 weeks)
Trial: 22291886
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 µg orally
Trial: 22291886
Drug: Clonidine 75
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 75 µg orally
Trial: 22291886
Drug: Clonidine 0
RxNorm normalized name: clonidine 0.17 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0 µg (placebo)
Trial: 16362593
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin 1x 20 microg for 2 months
Trial: 16362593
Drug: Conditioning therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning therapy for 2 months
Trial: 16362593
Drug: Intranasal isotonic
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal isotonic solutions (placebo)
Trial: 10073511
Drug: mifepristone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mifepristone (all doses)
Trial: 2149565
Drug: Trazodone hydrochloride
RxNorm normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trazodone hydrochloride (average dose 201 mg)
Trial: 2149565
Drug: Placebo (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (average dose 238 mg)
Trial: 30282056
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A)
Trial: 24990200
Drug: 5-mg once-daily
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mg once-daily tadalafil
Trial: 24990200
Drug: 5-mg alternate-day
RxNorm normalized name: Alternaria alternata allergenic extract 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg alternate-day tadalafil
Trial: 16830130
Drug: MDMA 0
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 0 mg with alcohol
Trial: 10997956
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (1.0 g CHO.kg body mass(‐1) prior to and 0.5 g CHO.kg body mass(‐1) every 10 minutes during IRT)
Trial: 26261114
Drug: Active learning
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active learning modules (case scenarios, critical appraisal of prescriptions, drug identification)
Trial: 23651425
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone undecanoate (1000 mg)
Trial: 18979716
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
Trial: 18979716
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies under preclinical investigation or early stage clinical trials
Trial: 10764418
Drug: Norepinephrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (10 micromol/L) exposure in isolated cardiomyocytes
Trial: 8650928
Drug: Wobenzym (enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wobenzym (enzyme therapy)
Trial: 8650928
Drug: Lynestrenol (hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lynestrenol (hormone therapy)
Trial: 1611639
Drug: Diltiazem 180
RxNorm normalized name: diltiazem 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 180 mg, 360 mg, and 540 mg once daily for two weeks
Trial: 6146045
Drug: Children not
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children not receiving vitamin A supplements (case-control analysis)
Trial: 29356207
Drug: Adjunctive mexiletine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive mexiletine therapy
Trial: 27021829
Drug: Parent involvement
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent involvement intervention (weekly newsletters and text messages for 5 weeks)
Trial: 24060708
Drug: Intensive interdisciplinary
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive interdisciplinary pain treatment (IIPT)
Trial: 22488252
Drug: Fluoride-supplemented milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride-supplemented milk (200 ml with 5 mg F/l as NaF once a day)
Trial: 22488252
Drug: Unsupplemented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupplemented milk (200 ml)
Trial: 18633021
Drug: Palonosetron 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.025 mg
Trial: 18633021
Drug: Palonosetron 0.050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.050 mg
Trial: 2066455
Drug: High-dose fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluoxetine (median 80 mg/day)
Trial: 2066455
Drug: Standard-dose imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose imipramine (median 200 mg/day)
Trial: 6190888
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole alone
Trial: 6190888
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metronidazole and gentamicin
Trial: 6190888
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of bowel preparation (poor)
Trial: 29505321
Drug: Home Exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home Exercise Program (HEP) consisting of three static balance exercises: feet-together, single-leg stance, and tandem, performed twice for 30-60 seconds, once per day, 3 days per week for 12 weeks.
Trial: 24832388
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg fentanyl (group F)
Trial: 24832388
Drug: 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg dexmedetomidine (group D0.5)
Trial: 24832388
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg dexmedetomidine (group D1.0)
Trial: 20437859
Drug: Short-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiation plus adjuvant temozolomide (150-200 mg/m² for 5 days every 28-day cycle)
Trial: 9513589
Drug: 23 valent
RxNorm normalized name: pneumococcal polysaccharide vaccine, 23 valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 valent pneumococcal vaccine
Trial: 7608314
Drug: GITS (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GITS (240 mg)
Trial: 7608314
Drug: GITS (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GITS (120 mg)
Trial: 7608314
Drug: PeHCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PeHCl solution (given every 6 hours)
Trial: 7608314
Drug: Timed-release 12-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed-release 12-hour pseudoephedrine capsule (given every 12 hours)
Trial: 2364843
Drug: Standard nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nicardipine (20 mg)
Trial: 2364843
Drug: Sustained-release nicardipine
RxNorm normalized name: nicardipine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nicardipine (30 mg twice a day)
Trial: 2364843
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of nicardipine
Trial: 30920602
Drug: Aerobic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic and resistance exercise intervention (supervised sessions thrice weekly for 16 weeks)
Trial: 26881502
Drug: Supraclavicular radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supraclavicular radiation therapy (SC‐RT)
Trial: 21044897
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in low RVP (≤ 50%)
Trial: 21044897
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in high RVP (> 50%)
Trial: 21044897
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in low RVP (≤ 50%) during late phase
Trial: 21044897
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in high RVP (> 50%) during late phase
Trial: 11697839
Drug: irinotecan 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 175 mg/m2 given on days 1 and 10, repeated every three weeks for a total of six courses
Trial: 3408037
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nicergoline
Trial: 21722959
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine (K2: 10 mg and 25 mg doses at 11 and 4 hours preoperatively)
Trial: 21722959
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine (K3: 5 mg, 10 mg, and 25 mg doses at 17, 11, and 4 hours preoperatively)
Trial: 21722959
Drug: 1-ketamine-injection (K1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-ketamine-injection (K1: 25 mg at 4 hours preoperatively)
Trial: 22233522
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors (CNI) continuation
Trial: 11407442
Drug: Targeted maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted maintenance pharmacotherapy
Trial: 11407442
Drug: Standard-dose maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose maintenance neuroleptic treatment
Trial: 11407442
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Targeted and Standard-dose)
Trial: 8986684
Drug: E1S (estrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1S (estrone sulfate) 0.625 mg
Trial: 8986684
Drug: EqS (equilin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EqS (equilin sulfate) 0.3 mg
Trial: 8986684
Drug: 17 alpha-ES
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-ES (17 alpha-dihydroequilin sulfate) 0.2 mg
Trial: 8275614
Drug: Naringin capsule
RxNorm normalized name: Naringin
DrugBank: Naringin (DB16859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringin capsule
Trial: 2886340
Drug: Beta-blockers +
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers + Chlorthalidone (BB + CTD)
Trial: 25363178
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg PRN and hydration (control group)
Trial: 18565217
Drug: Systemic methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic methotrexate (MTX) - single dose intramuscular regimen (1 mg/kg)
Trial: 16087057
Drug: ACTH treatment
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH treatment (n = 26)
Trial: 16087057
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid treatment (n = 18)
Trial: 12618533
Drug: High-dose ACTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ACTH
Trial: 11821278
Drug: Continued administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued administration of vaginal progesterone for 3 weeks after positive HCG (control group, n = 153)
Trial: 3929067
Drug: Chemo-immunotherapy consisting
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy consisting of Tegafur, Adriamycin (ADM), Mitomycin C (MMC) and OK432
Trial: 29709062
Drug: Chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy
Trial: 26699690
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia combined with infusion of 1 μg/kg dexmedetomidine
Trial: 18765877
Drug: 12 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 ml/kg Ringer lactate iv (Group B)
Trial: 18765877
Drug: 12 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 ml/kg 4.5% hydroxyethylstarch (Hetastarch) iv (Group C)
Trial: 18765877
Drug: 2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg Ringer lactate iv (Group A)
Trial: 15885641
Drug: Oral glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoid (prednisolone) therapy
Trial: 12665325
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment strategy (DAD)
Trial: 10378632
Drug: Ifosfamide (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 10 days (cohort A)
Trial: 10378632
Drug: Ifosfamide (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 7 days (cohort B)
Trial: 9081356
Drug: High uPA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High uPA tumours (uPA > 0.62 ng/mg protein)
Trial: 9081356
Drug: Not treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not treated with systemic adjuvant therapy
Trial: 30230026
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (n=56)
Trial: 27342507
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of bortezomib
Trial: 27342507
Drug: Reduction dose
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction dose of bortezomib
Trial: 22248153
Drug: Avanafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil (50 mg, 100 mg, 200 mg)
Trial: 17891409
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 1 g (Perfalgan)
Trial: 8764800
Drug: 0.7% dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7% dorzolamide twice daily
Trial: 3860335
Drug: Fluoride supplements
RxNorm normalized name: Fluoride supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride supplements (for children of mothers who received personal advice)
Trial: 15945446
Drug: Short-term controlled
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term controlled treatment (DOTS)
Trial: 15945446
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment regimens
Trial: 15945446
Drug: Quadruple-combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple-combination therapy
Trial: 15945446
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 5 antituberculous drugs
Trial: 12527599
Drug: AeroDose 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroDose 90 mg
Trial: 12527599
Drug: AeroDose 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroDose 30 mg
Trial: 12527599
Drug: AeroDose 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroDose 60 mg
Trial: 12527599
Drug: PARI LC
RxNorm normalized name: Pari LC Pediatric Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARI LC PLUS 300 mg
Trial: 12527599
Drug: AeroDose (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroDose (all doses)
Trial: 10473238
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g single dose)
Trial: 10473238
Drug: Vancomycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (500 mg i.v. every 6 h for 48 h)
Trial: 8888369
Drug: AMPT 1
RxNorm normalized name: AMPT
DrugBank: Racemetyrosine (DB16306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMPT 1 g
Trial: 8888369
Drug: Promethazine 50
RxNorm normalized name: promethazine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 50 mg (placebo)
Trial: 1676083
Drug: Psychosocial stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial stimulation (weekly play sessions at home with a community health aide)
Trial: 6603287
Drug: Digoxin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (1 mg iv over 24 hr, then 0.25 mg/day) and Propranolol (10 mg every 6 hr)
Trial: 26891420
Drug: Tivantinib (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (360 mg/m² twice daily) plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Trial: 26891420
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)